- Home
- CAPT vs IGC Comparison
CAPT vs IGC Comparison
Compare CAPT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- IGC
- Stock Information
- Founded
- CAPT 2005
- IGC 2005
- Country
- CAPT South Korea
- IGC United States
- Employees
- CAPT N/A
- IGC N/A
- Industry
- CAPT Blank Checks
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- CAPT Finance
- IGC Health Care
- Exchange
- CAPT Nasdaq
- IGC Nasdaq
- Market Cap
- CAPT 37.9M
- IGC 39.8M
- IPO Year
- CAPT N/A
- IGC N/A
- Fundamental
- Price
- CAPT $1.14
- IGC $0.41
- Analyst Decision
- CAPT
- IGC Strong Buy
- Analyst Count
- CAPT 0
- IGC 2
- Target Price
- CAPT N/A
- IGC $4.00
- AVG Volume (30 Days)
- CAPT 155.8K
- IGC 1.4M
- Earning Date
- CAPT 01-01-0001
- IGC 11-11-2025
- Dividend Yield
- CAPT N/A
- IGC N/A
- EPS Growth
- CAPT N/A
- IGC N/A
- EPS
- CAPT N/A
- IGC N/A
- Revenue
- CAPT $17,389,944.00
- IGC $1,327,000.00
- Revenue This Year
- CAPT N/A
- IGC $15.26
- Revenue Next Year
- CAPT N/A
- IGC $3.41
- P/E Ratio
- CAPT N/A
- IGC N/A
- Revenue Growth
- CAPT 84.70
- IGC 24.95
- 52 Week Low
- CAPT $0.37
- IGC $0.25
- 52 Week High
- CAPT $2.60
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- CAPT 44.61
- IGC 52.22
- Support Level
- CAPT $1.02
- IGC $0.38
- Resistance Level
- CAPT $1.16
- IGC $0.47
- Average True Range (ATR)
- CAPT 0.09
- IGC 0.04
- MACD
- CAPT 0.00
- IGC -0.00
- Stochastic Oscillator
- CAPT 52.38
- IGC 32.79
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.